SCHEMBL3166883

SCHEMBL3166883

C[C@H]([C@@H](O)c1ccccc1)N(C)C(=O)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 8/20 0.56
SCN1A P35498 5/20 0.56
SCN5A Q14524 5/20 0.56
SCN3A Q9NY46 3/20 0.56
SCN4A P35499 1/20 0.56
SCN9A Q15858 1/20 0.56
SCN2A Q99250 1/20 0.56
SCN10A Q9Y5Y9 1/20 0.56
SCN1B Q07699 6/20 0.53
LIMK2 P53671 2/20 0.53
RXFP1 Q9HBX9 1/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
TDP1 Q9NUW8 1/20 0.49
ALDH1A1 P00352 1/20 0.48
CA1 P00915 1/20 0.48
CYP3A4 P08684 1/20 0.48
PTGS1 P23219 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3163245 1.00 SCN8A (0.56) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3163253 1.00 SCN8A (0.56) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3166893 1.00 SCN8A (0.56) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3168368 0.89 LIMK2 (0.67) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3165520 0.83 SCN3A (0.59) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3168125 0.82 SCN8A (0.56) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3167341 0.81 SCN1A (0.54) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3165535 0.81 SCN8A (0.54) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3169340 0.79 SCN3A (0.65) SCN8ASCN1ASCN5ASCN3ASCN4A
SCHEMBL3173762 0.79 SCN3A (0.65) SCN8ASCN1ASCN5ASCN3ASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN8A 75/4885SCN1A 6/4885SCN5A 15/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN8A 75/4885SCN1A 6/4885SCN5A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.